...Good morning, everyone. Thanks for joining our Piper Sandler Healthcare Conference. My name is Yas Rahimi. I'm a Senior Biotech Analyst here at Piper, thrilled to be featuring the team of Altimmune here. We have lots to cover in the next 25 minutes. For the audience, if you do have a question, just raise your hand and we will pass the mic to you. Team, we are eagerly awaiting very upcoming -- [another catalyst -- very too big] two catalysts, one is more near-term, which is 24-week data from the NAFLD study mid-December. A question for you here is, which you have gotten many different ways here, what should we expect to see at this 24-week time point across all -- maybe what do we want to see in terms of weight loss? What should we want to see in lipid production, fat reduction in the liver, and liver enzyme? Sort of like a broad picture of what is a fair expectation in this particular population? And then part two is why is this population so unique from the typical obese MOMENTUM study...
